Revised Press Release on Unaudited Financial Results for the quarter ended June 30, 2026
RESULTS
▼ Concern Flagged
MEDIUM RISK
📅 Filed on BSE: 21 Jul 2026, 07:25 PM IST · BSE ID: 03875104-520e-43d9-bb0c-80688ffbe5ce
View Original BSE Filing (PDF)
💡
In Simple Terms
Anthem Biosciences' Q1 FY27 profit and revenue decreased compared to the previous year, though margins remained notable.
🤖 AI Summary
- Anthem Biosciences reported Q1 FY27 consolidated Profit after tax of ₹1,199 Mn, a decrease of 11.7% YoY.
- Consolidated Revenue from Operations for Q1 FY27 was ₹4,182 Mn, down 22.6% from ₹5,402 Mn YoY.
- EBITDA for the quarter stood at ₹1,755 Mn, with EBITDA margins at 39.6% for Q1 FY27.
- CRDMO business revenue was ₹3,408 Mn, while Specialty Ingredients contributed ₹774 Mn.
- Total Revenues for Q1 FY27 reached ₹4,431 Mn, showing a 21.3% decrease YoY.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Revenue from Operations
₹4,182 Mn
-22.6%
Profit after tax
₹1,199 Mn
-11.7%
CRDMO Revenue
₹3,408 Mn
-24.7%
Specialty Ingredients Revenue
₹774 Mn
-11.5%
🏢 How This Affects the Company
The CRDMO business revenue decreased by 24.7% YoY to ₹3,408 Mn, while Specialty Ingredients revenue declined by 11.5% YoY to ₹774 Mn. Management attributed this to timing shifts in deliveries.
Consolidated Profit after tax decreased by 11.7% YoY to ₹1,199 Mn. Consolidated Revenue from Operations declined by 22.6% YoY to ₹4,182 Mn. EBITDA margins stood at 39.6% and PAT margins at 27.1% for the quarter.
Not applicable — the filing does not contain specific operational impact details beyond financial figures.
Not applicable — the filing does not contain specific risk impact details.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required by shareholders based on this financial results filing.
👤
Who Is Affected
All shareholders are affected by the reported financial performance, showing a decrease in both revenue and profit for the quarter ended June 30, 2026.
🔍
Management Signal
Management signals commitment to sustaining revenue growth in line with historical performance, citing timing shifts in deliveries and focus on cost efficiencies.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Earnings call on July 22, 2026, to discuss financial and business performance.
Q2 FY27 results — monitor for signs of revenue recovery and delivery shifts.
Commentary on underlying demand and scheduled deliveries in latter half of FY27.
MEDIUM RISK
Significant YoY and QoQ declines in key financial metrics indicate business headwinds.
💡 Investor Takeaway
Anthem Biosciences reported Q1 FY27 consolidated Profit after tax of ₹1,199 Mn, down 11.7% YoY from ₹1,358 Mn. Revenue from Operations decreased 22.6% YoY to ₹4,182 Mn. EBITDA margins were 39.6% and PAT margins 27.1%.
⚖️ Strengths & Concerns
✅ Positives
- EBITDA margins for Q1 FY27 were 39.6% (₹1,755 Mn), indicating a strong profitability profile despite revenue decline.
- PAT margins were 27.1% (₹1,199 Mn), reflecting robust net profitability for the quarter.
⚠️ Concerns
- Consolidated Revenue from Operations decreased by 22.6% YoY to ₹4,182 Mn in Q1 FY27, indicating a significant top-line contraction.
- Consolidated Profit after tax decreased by 11.7% YoY to ₹1,199 Mn, reflecting lower net earnings compared to the prior year.
📅 Company Track Record
Previous filing on July 21, 2026, indicated Anthem Biosciences' Q1 FY27 profit decreased to Rs. 1,020.09 Mn. This revised press release supersedes the earlier submission with updated figures.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What was Anthem Biosciences' consolidated net profit for Q1 FY27?
Anthem Biosciences reported a consolidated Profit after tax of ₹1,199 Mn for the quarter ended June 30, 2026, which is an 11.7% decrease YoY.
What was Anthem Biosciences' Revenue from Operations in Q1 FY27?
Consolidated Revenue from Operations for Anthem Biosciences in Q1 FY27 was ₹4,182 Mn, marking a 22.6% decrease compared to Q1 FY26's ₹5,402 Mn.
What were the EBITDA and PAT margins for Anthem Biosciences in Q1 FY27?
Anthem Biosciences' EBITDA for Q1 FY27 was ₹1,755 Mn, with EBITDA margins at 39.6%. PAT for the quarter was ₹1,199 Mn, resulting in PAT margins of 27.1%.
How did Anthem Biosciences' CRDMO and Specialty Ingredients segments perform in Q1 FY27?
The CRDMO business generated ₹3,408 Mn in revenues, a 24.7% YoY decrease, while Specialty Ingredients delivered ₹774 Mn, a 11.5% YoY decrease for Q1 FY27.
Questions based on this BSE filing only. For information purposes.